Publication List

 

 

Books

 

Müller, R.H., Mehnert, W. Particle and Surface Characterisation, medpharm Scientific Publishers, Stuttgart (1997).

 

Wätzig, H., Mehnert, W., Bühler, W. Mathematik und Statistik kompakt, Wissenschaftliche Verlagsgesellschaft (2009).

 

Book Chapters

 

Mehnert W. Phytopharmaka–Vergleichende Qualitätsbeurteilung, in: Pharmazeutische Technologie:Moderne Arzneiformen. R.H. Müller, G. Hildebrand, (eds) 2.Auflage,Wissenschaft-

liche Verlagsgesellschaft, Stuttgart, 109-118 (1998).

 

Mehnert, W., Therapeutische Äquivalenz, in: Lehrbuch der Klinischen Pharmazie. Jaehde, U., Radziwill, R., Mühlebach, S., Schunack, W. (eds.), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 39-53 (1998).

 

Mehnert, W., Bioverfügbarkeit, Bioäquivalenz, in: Grundlagen der Arzneiformenlehre, Galenik 2. Herzfeldt, C.-D., Kreuter, J., (eds), Springer-Verlag Berlin, 510-535 (1999).

 

Böhning, D., Malzahn, U., Schlattmann, P., Dammann, U.-P., Mehnert, W., Holling, H., Schulze, R. The Application of Statistical Methods of Meta-Analysis for Heterogeneity Modelling in Medicine, Pharmacy, Psychology, Quality Control and Assurance, in: Mathematics – Key Technology for the Future. Jäger, W., Krebs, H.-J. (eds), Springer-Verlag Heidelberg, 533-553 (2003).

 

Mehnert, W., Therapeutische Äquivalenz, in: Lehrbuch der Klinischen Pharmazie. Jaehde, U., Radziwill, R., Mühlebach, S., Schunack, W. (eds.), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 49-66 (2003), 2. Auflage.

 

Schäfer-Korting M., Mehnert W.: Delivery of lipophilic compounds with lipid nanoparticles – application in dermatics and for transdermal therapy. In: Nastruzzi C (ed) Liposheres in Drug Targets and Delivery: Approaches, Methods, and Applications,CRC Press, Boca Raton, 127-142 (2005)

 

Mäder K.,  Mehnert W.: Solid lipid nanoparticles – concepts, procedures and physicochemical aspects. In: Nastruzzi C (ed) Liposheres in Drug Targets and Delivery: Approaches, Methods, and Applications. CRC Press, Boca Raton, 1-22 (2005)

 

Müller, R. H., Mehnert, W., Souto, E.B.: Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for dermal delivery. In: Bronaugh (eds) Percutaneous Absorption. Marcel Dekker, Inc., New York, Basel, Hong-Kong, 719-738 (2005)

 

 

Review Articles

 

K.-H. Frömming, W. Mehnert. Arzneimittelwirkung und Nahrungsaufnahme. Der informierte Arzt 2, 4 (1981).

 

W. Mehnert, D. Ohlendorf. Bioverfügbarkeit – Bioäquivalenz.Eine Check-Liste.

Krankenhauspharmazie 8, 55 (1987).

 

R. H. Müller, W. Mehnert. Neue Arzneimittel mit Nanopartikeln. Dtsch. Apoth. Ztg. 135, 2597 (1995).

 

M. Eder, W. Mehnert. Bedeutung pflanzlicher Begleitstoffe in Extrakten. Pharmazie 53, 285-293 (1998).

 

Eder, M., Mehnert, W.: Pflanzliche Begleitstoffe – wertvolle Hilfsstoffe oder überflüssiger Ballast? Pharmazie in unserer Zeit, 29/6, 377-384 (2000).

 

Mehnert, W., and K. Mäder. Solid lipid nanoparticles. Production, characterization and applications. Adv Drug Deliv Rev 47(2-3):165-96 (2001).

 

W. Mehnert. Lipid-Nanodispersionen – kolloidales Trägersystem zur dermalen Applikation. SwissPharma 24: 13-16(2002).

 

Danker, K., Dathe, M., Kleuser, B., Kramer, K., Liesenfeld, O., Mehnert, W., Niehus, H., Reutter, W. und M. Schäfer-Korting. Innovative Wirkstoffe und Carriersysteme für eine gezielte Arzneimitteltherapie. BIOspektrum 9: 315-317 (2003).

 

Mehnert, W. Thermoanalytische Verfahren und ihre Anwendung in der Praxis. PZ Prisma 11: 223-232 (2004).

 

Schäfer-Korting, M., Mehnert, W., Korting, H.-C.: Lipid nanoparticles for improved topical application of drugs for skin diseases. Advanced Drug Delivery Reviews 59: 427-443 (2007).

 

 

 

Research Articles

 

G. Vetter, W. Mehnert, K.-H. Frömming. In vitro-/In vivo-Korrelation nach Einnahme mikroverkapselter Acetylsalicylsäure mit einem Fruchtsaftgetränk. Acta Pharm. Technol. 27, 109 (1981).

 

K.-H. Frömming, W. Mehnert, G. Vetter. Beeinflussung der relativen Bioverfügbarkeit von Riboflavin durch eine Einnahmeflüssigkeit. Arzneim.-Forsch. 31, 2159 (1981).

 

K.-H. Frömming, W. Mehnert, G. Vetter. Über den Einfluß eines Fruchtsaftgetränkes auf die Magenentleerungs­geschwindigkeit und die Bioverfügbarkeit von Acetylsalicylsäure. Dtsch. Apoth. Ztg. 121, 373 (1981).

 

W. Mehnert, G. Vetter, K.-H. Frömming. Über den Einfluß eines Fruchtsaftgetränkes auf die in vitro-Wirkstoff-Freisetzung aus mikroverkapselter Acetylsalicylsäure. Dtsch. Apoth. Ztg. 121, 501 (1981).

 

K.-H. Frömming, V. Wedelich, W. Mehnert. Influence of Cyclodextrins on Nitrosation of Drugs.

J. Inclus. Phenom. 2, 605 (1984).

 

K.-H. Frömming, V. Wedelich, W. Mehnert, A. Lange, R. Hosemann. Einschlußverbindungen von Cyclodextrinen mit Piperazin. Arch. Pharm. 320, 294 (1987).

 

V. Wedelich, W. Mehnert, K.-H. Frömming. In Vitro Nitrosation of Ephedrine in the Presence of Cyclodextrins. J. Inclus. Phenom. 5, 621 (1987).

 

K.-H. Frömming, V. Wedelich, W. Mehnert. Nitrosation of Mefenorex in the Presence of Cyclodextrins. J. Inclus. Phenom. 5, 625 (1987).

 

J. Szulecki, A. Kubis, W. Mehnert, K.-H. Frömming. Untersuchungen über mit Methylcellulosen behandelte Brandwundverbände. Pharm. Ztg. Wiss. 1, 56 (1988).

 

K.-H. Frömming, T. Gelder, W. Mehnert. Inclusion Compound of ß-Cyclodextrin and Vitamin A Acetate. Acta Pharm. Technol. 34, 152 (1988).

 

K.-H. Frömming, N. Eisenbach, W. Mehnert.Beeinflussung biopharmazeutischer Eigenschaften von Arzneistoffen durch pflanzliche Begleitstoffe am Beispiel von Khellin in einem Ammi visnaga-Trockenextrakt. Pharm. Ind. 51, 439 (1989).

 

K.-H. Frömming, C. Kraus, W. Mehnert. Physico-Chemical Properties of the Mixed Micellar Solutions of Solutol HS 15 and Sodium Deoxycholate. Acta Pharm. Technol. 36, 214 (1990)

 

C. Kraus, W. Mehnert, K.-H. Frömming. Hemolytic Activity of Mixed Micellar Solutions of Solutol HS 15 and Sodium Deoxycholate. Acta Pharm. Technol. 36, 221 (1990).

 

C. Kraus, W. Mehnert, K.-H. Frömming. Interactions of ß-Cyclodextrin with Solutol HS 15 and their Influence on Diazepam Solubilization. Pharm. Ztg. Wiss. 4, 11 (1991).

 

K.-H. Frömming, R. Fridrich, W. Mehnert. Inclusion Compounds of Cholesterol and ß-Cyclodextrin. Eur. J. Pharm. Biopharm. 39, 148 (1993).

 

R. Schuhmann, W. Mehnert, R.H. Müller. Stability of O/W Emulsion I: Coulter Counter based Coalescence Assay to determine the Stability of Emulsions against Addition of Electrolyte. Pharm. Industrie 55, 701 (1993).

 

C. Schwarz, W. Mehnert, J.-S. Lucks, R.H. Müller. Solid Lipid Nanoparticles (SLN) for Controlled Drug Delivery. I: Production, Characterization and Sterilisation. Journal of Controlled Release 30, 83 (1994).

 

V. Bothmann, W.G. Schmidt, W. Mehnert, K.-H. Frömming. Herstellung von Pellets in einem Labor-Rotorgranulator. Pharm. Industrie 56, 570 (1994).

 

A. Preiss, W. Mehnert, K.-H. Frömming. Complexation of Hydrocortison with ß-Cyclodextrin and Hydroxy-propyl-ß-Cyclodextrin. Arch. Pharm. 327, 729 (1994).

 

A. Preiss, W. Mehnert, K.-H. Frömming. In vitro hydrocortisone release from ointments in presence of cyclodextrins. Pharmazie 49, 902 (1994).

 

R. H. Müller, W. Mehnert, J.-S. Lucks, C. Schwarz, A. zur Mühlen, H. Weyhers, C. Freitas, D. Rühl. Solid Lipid Nanoparticles (SLN) - An Alternative Colloidal Carrier System for Controlled Drug Delivery. Eur. J. Pharm. Biopharm. 41, 62 (1995).

 

A. Preiss, W. Mehnert, K.-H. Frömming. The Inclusion Compound of Emulsified Cetostearyl Alcohol with ß- Cyclodextrin and a Competitive Reaction with a Hydrocortisone/ß- Cyclodextrin Inclusion Compound in an Oil-in-Water Cream. Journal of Inclusion Phenomena and Molecular Recognition in Chemistry  18, 331 (1994).

 

A. Preiss, W. Mehnert, K.-H. Frömming. Penetration of hydrocortisone into excised human skin under theinfluence of cyclodextrins. Pharmazie 50, 121 (1995).

 

W. G. Schmidt, W. Mehnert, K.-H. Frömming. Controlled Release of Theophylline from Spherical Matrices Preparedin a Laboratory Scale Rotor-Granulator  -  Variation of Release Rate and Initial Release. Eur. J. Pharm. Biopharm. 41, 132 (1995).

 

H. Haubitz, W. Mehnert, K.-H. Frömming Preparation of Theophylline Multiple Units Tablets.

Pharm. Ind. 58, 83 (1996).

 

H. Weyhers, W. Mehnert, R. H. Müller. Analysis of Particle Size Distribution of Micronized Lactose by Laser Diffractometry. Pharm. Ind. 58, 354 (1996).

 

M. Bergmann, W. Mehnert, K.-H. Frömming. Dependence of Quality of Freeze-Dried Diazepam-Mannitol on Some Processing Conditions. Eur. J. Pharm. Biopharm. 42, 171 (1996).

 

A. zur Mühlen, E. zur Mühlen, H. Niehus, and W. Mehnert. Atomic Force Microscopy Studies of Solid Lipid Nanoparticles. Pharm. Res. 13, 1411 (1996).

 

W. G. Schmidt, W. Mehnert, K.-H. Frömming. Controlled Release from Spherical Matrices Prepared in a Laboratory Scale Rotor-Granulator - Release Mechanism Interpretation Using Individual Pellet Data. Eur. J. Pharm. Biopharm. 42, 348 (1996).

 

R.H. Müller, S. Maaßen, H. Weyhers, W. Mehnert. Phagozytic Uptake and Cytotoxicity of Solid Lipid Nanoparticles (SLN) Sterically Stabilized with Poloxamine 908 and Poloxamer 407. Journal of Drug Targeting 4, 161 (1996).

 

R.H. Müller, D. Rühl, S. Runge, K. Schulze-Forster, W. Mehnert. Cytotoxicity of Solid Lipid Nanoparticles as a Function of the Lipid  Matrix and the Surfactant. Pharm. Res. 14, 458 (1997).

 

R.H. Müller, S. Maassen, C. Schwarz, W. Mehnert. Solid lipid nanoparticles (SLN) as potential carrier for human use:  interaction with human granulocytes. Journal of Controlled Release 47, 261 (1997).

 

R. H. Müller, H. Weyhers, A. zur Mühlen, A. Dingler, W. Mehnert. Solid Lipid Nanoparticles - ein neuartiger Wirkstoff-Carrier für Kosmetika und Pharmazeutika, 1. Mitteilung: Systemeigenschaften, Herstellung und  Scaling up. Pharm. Ind. 59, 423 (1997).

 

W. Mehnert, A. zur Mühlen, A. Dingler, H. Weyhers, R.H. Müller. Solid Lipid Nanoparticles - ein neuartiger Wirkstoff-Carrier für Kosmetika und Pharmazeutika, 2. Mitt.: Wirkstoff-Inkorporation, Freisetzung und Sterilisierbarkeit. Pharm. Ind. 59, 511 (1997).

 

R.H. Müller, A. Dingler, H. Weyhers, A. zur Mühlen, W. Mehnert. Solid Lipid Nanoparticles - ein neuartiger Wirkstoff-Carrier für Kosmetika und Pharmazeutika, 3. Mitteilung: Langzeitstabilität, Gefrier- und Sprühtrocknung, Toxizität, Anwendung in Kosmetika und Pharmazeutika. Pharm. Ind. 59, 614 (1997).

 

C. Schwarz, W. Mehnert. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int. J. Pharm. 157, 171 (1997).

 

H. Weyhers, W. Mehnert, R. H. Müller. Analysis of Particle Size Distribution of Micronized Lactose by Laser Diffractometry. Drugs made in Germany 40, 66 (1997).

 

E. Berkel, W. Mehnert, K.-H. Frömming. Enzymatic Hydrolysis of Chloramphenicol Palmitate in Presence of ß-Cyclodextrin. Pharmazie 53, 323-326 (1998).

 

A. zur Mühlen, C. Schwarz, W. Mehnert. Solid Lipid Nanoparticles (SLN) for controlled drug delivery- drug release and release mechanism. Eur. J. Pharm. Biopharm. 45, 149-155 (1998).

 

C. Schwarz, W. Mehnert. Solid lipid Nanoparticles (SLN) for controlled drug delivery

II. Drug incorporation and physicochemical characterization. J Microencapsul 16: 205-13 (1999).

 

Eder, M., Mehnert, W.: Lösungsverhalten von Digoxin in Gegenwart pflanzlicher Begleitstoffe aus Digitalis-lanata-Trockenextrakten, Teil 1: Löslichkeit und Lösungsgeschwindigkeit. Pharmazie 55:928-933 (2000).

 

Maia, C.S., Mehnert, W., M. Schäfer-Korting. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm 196: 165-167 (2000).

 

Santos Maia, C., Mehnert, W., Schaller, M., Korting, H.C., Gysler, A., Haberland, A., and  M. Schäfer-Korting. Drug Targeting by Solid Lipid Nanoparticles for Dermal Use. J Drug Targeting 10: 489-495 (2002).

 

Haberland, A., Santos Maia, C., Jores, K., Dürrfeld, M., Mehnert, W., Schimke, I., Christ, B. and M. Schäfer-Korting. Albumin Effects on Drug Absorption and Metabolism in Reconstructed Epidermis and Excised Pig Skin. Altex 20: 3-9 (2003).

 

Jores, K., Mehnert, W. and K. Mäder. Physicochemical Investigations on Solid Lipid Nanoparticles and on Oil-Loaded Solid Lipid Nanoparticles: A Nuclear Magnetic Resonance and Electron Spin Resonance Study. Pharm Res 20: 1274-1283 (2003).

 

Jores, K., Mehnert, W., Drechsler, M., Bunjes, H., Johann, C. and K. Mäder. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release 95: 217-227 (2004).

 

Sivaramakrishnan R, Nakamura C, Mehnert W, Korting, HC, Kramer KD, Schäfer-Korting M: Glucocorticoid entrapment into lipid carriers – characterization by parelectric spectroscopy and influence on dermal uptake. J Contr Release 97: 493-502 (2004).

 

Münster, U., Nakamura, C., Haberland, A., Jores, K., Mehnert, W., Rummel, S., Schaller, M., Zouboulis, Ch., Blume-Peytavi, U. and M. Schäfer-Korting. RU 58841-myristate – a prodrug for topical treatment of acne and androgenetic alopecia. Pharmazie 60: 8-12 (2005).

 

Jores, K., Haberland, A., Wartewig, S., Mäder, K. and W. Mehnert. Solid Lipid Nanoparticles (SLN) and Oil-Loaded SLN Studied by Spectrofluorometry and Raman Spectroscopy. Pharm Res 22: 1887-1897 (2005).

 

Lombardi Borgia, S., Regehly, M., Sivaramakrishnan, R. Mehnert, W., Korting, H.C., Danker, K., Röder, B., Kramer, K.D. and M. Schäfer-Korting. Lipid nanoparticles for skin penetration enhancement – correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Contr Release 110: 151-163 (2005).

 

Müller, R.H., Runge, S., Ravelli, V., Mehnert, W., Thünemann, A:F. and E.B. Suoto. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm 317: 82-89 (2006).

 

Souto, E.B., Mehnert, W. and R.H. Müller. Polymorphic behaviour of Compritol®888 ATO as bulk lipid and as SLN and NLC. J Microencapsul 23: 417-433 (2006).

 

Weyhers, H., Löbenberg, R., Mehnert, W., Suouto, E.B. Kreuter, J. and R.H. Müller: In vivo Distribution of 125I-radiolabelled Solid Lipid Nanoparticles. Pharm Ind 68: 889-894 (2006).

 

Štecova, J., Mehnert, W., Blaschke, T., Kleuser, B., Sivaramakrishnan, R., Zouboulis, C.C., Seltmann, H., Korting, H.C., Kramer, K.D., and M. Schäfer-Korting. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm Res 24: 991-1000 (2007).

 

Braem, C., Blaschke, T., Panek-Minkin, G., Herrmann, W., Schlupp, P., Paepenmüller, T., Müller-Goymann, C., Mehnert, W., Bittl, R., Schäfer-Korting, M. and K.D. Kramer. Interaction of drug molecules with carrier systems as studied by parelectric spectroscopy and electron spin resonance. J

Contr Release 119: 128-135 (2007).

 

Lombardi Borgia, S., Schlupp, P., Mehnert, W., and M. Schäfer-Korting. In vitro Skin Absorption and Drug Release – a Comparison of Six Commercial Prednicarbate Preparations for Topical Use. Eur J Pharm Biopharm 68: 380-389 (2008).

 

Schäfer-Korting, M., Mahmoud, A., Lombardi Borgia, S., Brüggener, B., Kleuser, B., Schreiber, S., Mehnert, W. Reconstructed Epidermis and Full-Thickness Skin for Absorption Testing: Influence of the Vehicles used on Steroid Permeation. ATLA 36: 1-12 (2008).
Proceedings

 

K.-H. Frömming, J. Norwig, W. Mehnert. Menadione Inclusion Compounds with Mixtures of Natural Cyclodextrins. Proceedings of the Fourth International Symposium on Cyclodextrins (eds. O. Huber, J. Szejtli) in: Advances in Inclusion Science, Kluwer Academic Publishers, Dordrecht Boston London 1988, p. 277.

 

M. Thoss, J. Norwig, W. Mehnert, K.-H. Frömming. Improvement on Photostability of Several Essential Oils and Menadione by Natural Cyclodextrins. s. cit. 1, p. 355.

 

J. Norwig, T. Gelder, Ch. Kraus, W. Mehnert, K. Rehse, K.-H. Frömming. Some Interesting Aspects in 1H-NMR Spectroscopy by Cyclodextrin Complexation. s. cit. 1, p. 205.

 

K.-H. Frömming, W. Mehnert, P. Bady, C. Kraus, M. Stein, V. Wedelich. Competitive Reactions of Cyclodextrin Inclusion Compounds. Minutes 5th International Symposium on Cyclodextrins (ed. D. Duchêne) Editions de Santé, Paris 1990, p. 392.

 

R. Fridrich, W. Mehnert, K.-H. Frömming. Studies of the Inclusion Compound between ß-Cyclodextrin and Cholesterol. s. cit. 4, p. 299.

 

E.M. Berkel, W. Mehnert, K.-H. Frömming. Preparation and Characterization of a Chloramphenicol Palmitate/ß-Cyclodextrin Inclusion Compound. Minutes 6th International Symposium on Cyclodextrins (ed. D. Duchêne) Editions de Santé, Paris 1992, p. 393.

 

J.E. Diederichs, W. Mehnert, J.S. Lucks, R.H. Müller. Microviscosity measurements for the optimization ofliposome and emulsion formulations. Proceed. 6th Int. Conf. on Pharm. Technol. (APGI), Paris,June 2-4, vol. V, 148 (1992).

 

J.E. Diederichs, W. Mehnert, R.H. Müller. Differential Scanning Calorimetry of parenteral fat emulsions. Proceed. 6th Int. Conf. on Pharm. Technol. (APGI), Paris, June 2-4, vol. IV, 361 (1992).

 

R.H. Müller, C. Schwarz, W. Mehnert, J.S. Lucks. Production of Solid Lipid Nanoparticles (SLN) for Controlled Drug Delivery. Proceed. Intern. Symp. Control. Rel. Bioct. Mater. 20, 480 (1993).

 

S. Maaßen, C. Schwarz, W. Mehnert, J.S. Lucks, F. Yunis-Specht,B.W. Müller, R.H. Müller. Comparison of Cytotoxicity between Polyester Nanoparticles and Solid Lipid Nanoparticles (SLN).

Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 20, 490 (1993).

 

R. H. Müller, C. Schwarz, A. zur Mühlen, W. Mehnert. Incorporation of lipophilic Drugs and Drug Release Profiles of  Solid Lipid Nanoparticles (SLN). Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 21, 146 (1994).

 

C. Schwarz, W. Mehnert. Sterilization of Drug-free and Tetracaine-loaded Solid Lipid Nanoparticles (SLN). Proc. 1st World Meeting APGI/APV, Budapest (1995), 485.

 

C. Schwarz, C. Freitas, W. Mehnert, R. H. Müller.Sterilization and Physical Stability of Drug-free and Etomidate-loaded Solid Lipid Nanoparticles. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 22, 766 (1995).

 

A. zur Mühlen, W. Mehnert. Drug Incorporation and Delivery of Prednisolone Loaded Solid Lipid Nanoparticles. Proc. 1st. World Meeting APGI/APV, Budapest (1995), 455.

 

R. H. Müller, W. Mehnert. Potential of Solid Lipid Nanoparticles (SLN) for Controlled Drug Delivery. Proc. 1st World Meeting APGI/APV, Budapest (1995), 463.

 

H. Weyhers, S. Ehlers, W. Mehnert, H. Hahn, R. H. Müller. Solid Lipid Nanoparticles - Determination of In Vivo Toxicity. Proc. 1st World Meeting APGI/APV, Budapest (1995), 489.

 

K.-H. Frömming, M. Bergmann, W. Mehnert. Dependence of Quality of Freeze-dried Diazepam Mannitol on some Manufacturing Conditions. Proc. 1st World Meeting APGI/APV, Budapest (1995), 985.

 

C. Olbrich, W. Mehnert, R.H. Müller. Effect of surfactant and lipid composition on the in vitro degradation time  of solid lipid nanoparticles (SLN). Proceed. Int. Symp. Control. Rel. Bioact. Mater. 24, 921 (1997).

 

R.H. Müller, W. Mehnert, A. Dingler, S.A. Runge, A. zur Mühlen, C. Freitas. Solid lipid nanoparticles (SLNTM, LipopearlsTM) - present state of  development. Proceed. Int. Symp. Control. Rel. Bioact. Mater. 24, 923 (1997).

 

Anger, S., Mehnert, W., Caldwell, K., R. H. Müller. High resolution determination of adsorption layer mass on particles by sedimentation Field-Flow-Fractionation. Proceed. 2nd World Meeting APGI/APV, Paris (1998), 643-644.

 

Olbrich, C., Mehnert, W., R. H. Müller.In vitro degradation properties of solid lipid nanoparticles (SLNÒ). Proceed. 2nd World Meeting APGI/APV, 25/28 May 1998, 577-578.

 

Olbrich, C., Mehnert, W., R. H. Müller. Development of an in vitro degradation assay for solid lipid nanoparticles (SLNÒ).  Proceed. 2nd World Meeting APGI/APV, 25/28 May 1998, 627-628.

Maia, C., A. Gyler, W. Mehnert, R. H. Müller, M. Schäer-Korting. Local tolerability of Solid lipid Nanoparticles for dermal use. Int. Symp. Control. Rel. Bioact. Mater. 26: 403-404 (1999).

 

Olbrich, C., Runge, S.A., Mehnert, W., Thünemann, A.F., R. H. Müller.(2000) Entrapment efficacy and biodegradation of cyclosporine loaded solid lipid nanoparticles (SLN) for peroral administration. Proceed 3rd World Meeting APV/APGI, Berlin.

 

Liedtke, S., Jores, K., Mehnert, W., and K. Mäder. Possibilities of non-invasive physico­chemical characterisation of colloidal drug carriers. Proceed Intern Symp Control Rel Bioact Mater 27: 1088-1089 (2000).

 

Jores, K., Liedtke, S., Mehnert, W., and K. Mäder. Characterization of solid lipid nano­parti­cles (SLN™) – how to optimize the quantity of surfactants. Proceed Intern  Symp Control Rel Bioact  Mater 27: 1092-1093 (2000).

 

Jores, K., Mehnert, W., Bunjes, H., Drechsler, M. and K. Mäder. From solid lipid nanoparticles (SLN) to nanospoons. Visions and reality of colloidal lipid dispersions. Proceed Intern  Symp Control Rel Bioact  Mater 30: 181 (2003).

 

 

 

 

Abstracts

 

Ch. Kraus, W. Mehnert, K.-H. Frömming. Lösungsvermittlung durch mischmizellare Systeme und deren Charakterisierung. Arch. Pharm. 320, 978 (1987).

 

V. Bothmann, W. Mehnert, K.-H. Frömming. Laboratory scale production of polymer matrix pellets. Acta Pharm. Technol. 34, 17 S (1988).

 

J. Norwig, M. Thoss, W. Mehnert, K.-H. Frömming. Röntgendiffraktometrische Untersuchungen an -Cyclodextrin-Einschlußverbindungen. Arch. Pharm. 322, 765 (1989).

 

K.-H. Frömming, J. Norwig, W. Mehnert. Bildung von Menadion-Cyclodextrin-Einschlußverbin-

dungen unter Verwendung von Cyclodextrin-Gemischen. Acta Pharm. Technol. 36, 40 S (1990).

 

W.G. Schmidt, W. Mehnert, K.-H. Frömming. Steuerung der Arzneistofffreisetzung aus Matrixpellets. Arch. Pharm. 323, 770 (1990).

 

W.G. Schmidt, W. Mehnert, K.-H. Frömming. Spherical Matrices with Apparent Zero-Order Release. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 18, 161 (1991).

 

A. Preiss, W. Mehnert, K.-H. Frömming. Die Beeinflussung der Hydrocortison-Liberation aus Dermatika durch Cyclodextrine. Eur. J. Pharm. Biopharm. 38, 48 S (1992).

 

H. Haubitz, W. Mehnert, K.-H. Frömming. Aufbau eines prozeßgesteuerten Labor-Rotor-Wirbelschichtgranulators zur Herstellung von Retard-Pellets. Eur. J. Pharm. Biopharm. 38, 49 S (1992).

 

J. E. Diederichs, W. Mehnert, J. S. Lucks, R. H. Müller. DSC Investigations of Parenteral Fat Emulsions. Eur. J. Pharm. Biopharm. 38, 32 S (1992).

R. Schuhmann, W. Mehnert, R. H. Müller. Coaleszence Kinetics of Fat Emulsions determined by Coulter Counter Measurements. Eur. J. Pharm. Biopharm. 38, 43 S (1992).

 

M. Eder, W. Mehnert, K.-H. Frömming..Influence of Natural Concomitant Compounds on Dissolving Properties of Digoxin. Eur. J. Pharm. Biopharm. 40, 5 S (1994).

 

H. Weyhers, W. Mehnert, R. H. Müller. Production and Charakterization of Surface-modified "Solid Lipid Nanoparticles" (SLN). Eur. J. Pharm. Biopharm. 40, 15 S (1994).

 

C. Schwarz, W. Mehnert, R. H. Müller. Influence of Production Parameters of Solid Lipid Nanoparticles (SLN) on the Suitability for Intravenous Injection. Eur. J. Pharm. Biopharm. 40, 24 S (1994).

 

C. Freitas, W. Mehnert, R. H. Müller. Stabilization of "Solid Lipid Nanoparticles" (SLN) by Spray Drying. Eur. J. Pharm. Biopharm. 40, 29 S (1994).

 

S. Maaßen, H. Weyhers, W. Mehnert, R. H. Müller. Surface-Modified Solid Lipid Nanoparticles (SLN) - In Vitro Affinity to Human Granulocytes. Eur. J. Pharm. Biopharm. 40, 41 S (1994).

 

C. Schwarz, W. Mehnert, R. H. Müller. Influence of Drug Incorporation and Lyophilisation on the Physical Stability of Solid Lipid Nanoparticles (SLN). Eur. J. Pharm. Biopharm. 40, 52 S (1994).

 

A. zur Mühlen, J.S. Lucks, W. Mehnert, R. H. Müller. Longterm Stability of "Solid Lipid Nanoparticles" (SLN) for Parenteral Application. Eur. J. Pharm. Biopharm. 40, 53 S (1994).

 

D. Rühl, S. Maaßen, C. Schwarz, W. Mehnert, R. H. Müller. Comparative Cytotoxicity of Solid Lipid Nanoparticles (SLN), Polyester and Cyanoacrylate Particles. Eur. J. Pharm. Biopharm. 40, 61 S (1994).

 

A. zur Mühlen, C. Schwarz, W. Mehnert, R. H. Müller. Produktion von "solid lipid nanoparticles" (SLN) für die kontrollierte Arzneistoffapplikation. Arch. Pharm. 326, 752 (1993).

 

A. Preiss, W. Mehnert, K.-H. Frömming. Die Beeinflussung der Hydrocortison-Penetration in  excidierte Humanhaut durch Cyclodextrine. Arch. Pharm. 326, 745 (1993).

 

M. Sieve, W. Mehnert, K.-H. Frömming. Die Abhängigkeit der Lyophilisatqualität von einigen Verfahrensparametern unter besonderer Berücksichtigung des Restlösungsmittelgehalts. Arch. Pharm. 326, 735 (1993).

 

C. Schwarz, W. Mehnert, R. H. Müller. Lyophilization of Solid Lipid Nanoparticles (SLN).

Eur. J. of Pharmaceutical Sciences 2, 177 (1994).

 

A. zur Mühlen, E. zur Mühlen, H. Niehus, W. Mehnert. Characterisation of Solid Lipid Nanoparticles by Atomic Force Microscopy. Eur. J. of Pharmaceutical Sciences 2, 178 (1994)

 

J. Dechandt, W. Mehnert, K.-H. Frömming.Influence of Hydroxypropyl--Cyclodextrin on the Antimicrobial. Eur. J. of Pharmaceutical Sciences 2, 179 (1994).

 

A. zur Mühlen, W. Mehnert. Freisetzung von Prednisolon aus „Solid Lipid Nanoparticles“ (SLN).

Abstract-Band, S. 54, Jahrestagung der DPhG, Jena, 20.-24.9.1995.

 

H. Weyhers, M. Lück, W. Mehnert, R. H. Müller. Feste Lipid Nanopartikel - Inkorporierung von hydrophilen Arzneistoffen. Abstract-Band, S. 161, Jahrestagung der DPhG, Jena, 20.-24.9.1995.

 

A. zur Mühlen, E. zur Mühlen, H. Niehus, W. Mehnert. Atomic Force Microscopy Investigations of Solid Lipid Nanoparticles. Eur. J. Pharm. Biopharm. 42 (Suppl.), 40 S (1996).

 

S. Runge, A. zur Mühlen, W. Mehnert, R. H. Müller.SLN Production with Surfactants Suitable for I.V. Administration - Effect of Production Parameters. Eur. J. Pharm. Biopharm. 42 (Suppl.), 41 S (1996).

 

H. Weyhers, W. Mehnert, J. Kreuter, R. H. Müller.  Radiolabelling of Solid Lipid Nanoparticles (SLN). Eur. J. Pharm. Biopharm. 42 (Suppl.), 42 S (1996).

 

 S. Runge, W. Mehnert, R. H. Müller.  SLN (Solid Lipid Nanoparticles), a Novel Formulation for the Oral Administration of Drugs. Eur. J. of Pharmaceutical Sciences 4 (Suppl.), S132 (1996).

 

R. H. Müller, C. Freitas, A. zur Mühlen, W. Mehnert. Long Term stability Investigations of Solid Lipid Nanoparticles (SLN). Eur. J. of Pharmaceutical Sciences 4 (Suppl.), S132 (1996).

 

R. H. Müller, C. Freitas, A. zur Mühlen, W. Mehnert. Solid lipid nanoparticles (SLN) for controlled drug delivery. Eur. J. of Pharmaceutical Sciences 4 (Suppl.), S75 (1996).

 

Liedtke, S., Mehnert, W., Mügge, C., and K. Mäder. Resonance spectroscopic methods for the characterisation of colloidal drug carriers. Arch Pharm Pharm Med Chem 333, Suppl. 2: 20 (2000).

 

Jores, K., Liedtke, S., Mäder, C., and W. Mehnert. Characterization of tensides in colloidal drug carrier systems. Arch Pharm Pharm Med Chem 333, Suppl. 2: 21 (2000)

 

Liedtke, S., Mehnert, W., and K. Mäder.  Dependence of  drug incorporation in lipid carrier systems on the drugs structure – an ESR study. Arch Pharm Pharm Med Chem 334, Suppl. 2: 24 (2001).

 

Jores, K., Mehnert, W., and K. Mäder. Incorporation of drug model substances in colloidal lipid carrier systems. Arch Pharm Pharm Med Chem 334, Suppl. 2: 77 (2001).

 

Jores, K., Mehnert, W., and K. Mäder. Non-invasive determination of the fate of colloidal lipid nanodispersions on human skin. Arch Pharm Pharm Med Chem 335, Suppl. 1: 113 (2002).

 

Mäder, K., Jores, K., Mehnert, W., and T. Plauschin. Non-invasive characterization of drug release processes by Low Frequency (1.2 GHZ) EPR-Imaging. Arch Pharm Pharm Med Chem 335, Suppl. 1: 115 (2002).

 

Mehnert, W., Jores, K., and K. Mäder. Lipid nanoparticles as possible drug carriers: a physicochemical characterization by spectrofluorometric studies. Arch Pharm Pharm Med Chem 335, Suppl. 1: 117 (2002).

 

Wissing, S. A., Mehnert, W., and R. H. Müller. SLN for topical products: In vitro model and in vivo effects. Arch Pharm Pharm Med Chem 335, Suppl. 1: 124 (2002).

 

Münster, U., Nakamura, C., Jores, K., Mehnert, W., Rummel, S., Schaller, M., Korting, H. C., and M. Schäfer-Korting. RU 58841-myristate – a new prodrug with promising properties for acne and androgenetic alopecia. Arch Pharm Pharm Med Chem 335, Suppl. 1: 131 (2002).

 

Nakamura, C., Mehnert, W., Sivaramakrishnan, R., Kramer, K.D., Korting, H.C., Schäfer-Korting, M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. DPhG-Jahrestagung 2003

(8.-11.10.2003, Würzburg), Abstrakt-Band, S. 104.

 

Nakamura, C., Mehnert, W., Sivaramakrishnan, R., Kramer, K.D., Korting, H.C., Schäfer-Korting, M. Solid Lipid Nanoparticles for Glucocorticoid Targeting to Human Skin. Naunyn-Schmiedeberg`s Archives of Pharmacology 369, Supplement 1: R 7 (2004).

 

Nakamura, C., Braem, C., Sivaramakrishnan, R., Kramer, K.D., Schäfer-Korting, M., Mehnert, W. Solid Lipid Nanoparticles for Glucocorticoide Treatment of Skin Diseases. DPhG. Landesgruppe Berlin-Brandenburg, “Der wissenschaftliche Nachwuchs stellt sich vor” (5.7.2004, Berlin), Abstrakt-Band: P 17.

 

Stecova, J., Sivaramakrishnan, R., Mehnert, W., Kramer, K.D., Zouboulis, C.C., Schäfer-Korting, M. Innovative drug carriers for topical Cyproterone acetate therapy of androgenetic alopecia and acne, Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, 6.10.-9.10.2004, Regensburg, Abstract-Band S.148 (P P25).

 

Stecova, J., Schlupp, P., Mehnert, W., Kramer, K.D., Zouboulis, C.C., Schäfer-Korting, M. Nanostructered carriers for topical cyproterone acetate application to intact and stripped human skin, 9. Jahrestagung der Gesellschaft für Dermopharmazie, Wien, 14.-15. März 2005.

 

Braem, C., Herrmann, W., Mehnert, W., Blaschke, T., Kramer, K.D., Schäfer-Korting, M. Interaction of different lipid nanodispersions with spinlabelled cholestane. Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, 4.-7. Oktober 2006, Marburg, Abstrakt-Band S. 133 (T015).